Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer

Annals of Oncology

Volumn 23, Issue 7, 2012, Pages 1803-1808

  Sonpavde, G ^a   Matveev, V ^b   Burke, J M ^c   Caton, J R ^d   Fleming, M T ^e   Hutson, T E ^a   Galsky, M D ^f   Berry, W R ^g   Karlov, P ^h   Holmlund, J T ⁱ   Wood, B A ⁱ   Brookes, M ⁱ   Leopold, L ⁱ  

^a TEXAS ONCOLOGY   (United States)

^b N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^c ROCKY MOUNTAIN CANCER CENTERS   (United States)

^d Willamette Valley Cancer Center   (United States)

^e Virginia Oncology Associates   (United States)

^f Department of Hematology Oncology   (United States)

^g Cancer Centers of North Carolina   (United States)

^h City Clinical Oncology Center   (Russian Federation)

ⁱ Ascenta Therapeutics   (United States)

Author keywords

AT 101; Chemonaive; Docetaxel; First line therapy; Metastatic castration resistant prostate cancer; Small molecule Bcl 2 inhibitor

Indexed keywords

DOCETAXEL; ISOSORBIDE; PLACEBO; PREDNISONE;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER RISK; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HEART DISEASE; HIGH RISK PATIENT; HUMAN; ILEUS; LUNG EMBOLISM; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; VISCERAL METASTASIS;

EID: 84859423230     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr555     Document Type: Article

References (32)

1. Berthold DR, Pond GR, Soban F et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242-245.
2. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.
3. McDonnell TJ, Troncoso P, Brisbay SM et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52: 6940-6944.
4. Krajewska M, Krajewski S, Epstein JI et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996; 148: 1567-1576.
5. Stackhouse GB, Sesterhenn IA, Bauer JJ et al. p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol 1999; 162: 2040-2045.
6. Lebedeva I, Rando R, Ojwang J et al. Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. Cancer Res 2000; 60: 6052-6060.
7. Zeitlin BD, Joo E, Dong Z et al. Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2. Cancer Res 2006; 66: 8698-8706.
8. Meng Y, Tang W, Dai Y et al. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol Cancer Ther 2008; 7: 2192-2202.
9. Jiang J, Sugimoto Y, Liu S et al. The inhibitory effects of gossypol on human prostate cancer cells-PC3 are associated with transforming growth factor beta1 (TGFbeta1) signal transduction pathway. Anticancer Res 2004; 24: 91-100.
10. Lian J, Wu X, He F et al. A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum. Cell Death Differ 2011; 181: 60-71.
11. Paoluzzi L, Gonen M, Gardner JR et al. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood 2008; 111: 5350-5358.
12. Liu G, Kelly WK, Wilding G et al. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res 2009; 15: 3172-3176.
13. Saleh M, Pitot H, Holmlund J et al. Extended phase I trial of the oral pan-Bcl-2 inhibitor AT-101 by multiple dosing schedules in patients with advanced cancers. J Clin Oncol 2007; 25 (18S): 3583. ASCO Annual Meeting Proceedings Part I Abstracts.
14. MacVicar GR, Greco A, Reeves J et al. An open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with hormone refractory prostate cancer (HRPC). J Clin Oncol 2009; 27Suppl15s. (Abstr 5062).
15. Poiesz B, Reeves J, McNulty W et al. Preliminary report of an open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with docetaxel refractory prostate cancer. J Clin Oncol 2009; 27Suppl15s. (Abstr 5145).
16. Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-1159.
17. Armstrong AJ, Tannock IF, de Wit R et al. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer 2010; 463: 517-525.
18. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 379747: 1147-1154.
19. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 36421: 1995-2005.
20. Petrylak DP, Ankerst DP, Jiang CS et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006; 98: 516-521.
21. Wilson WH, O'Connor OA, Czuczman MS et al. Navitoclax, a targeted highaffinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010; 1112: 1149-1159.
22. Vogler M, Weber K, Dinsdale D et al. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ 2009; 16: 1030-1039.
23. Kingsley E, Richards D, Garbo L et al. An open-label, multicenter, phase II study of AT-101 in combination with rituximab (R) in patients with untreated, grade 1-2, follicular non-Hodgkin's lymphoma (FL). J Clin Oncol 2009; 27Suppl15s. (Abstr 8582).
24. Ready N, Karaseva NA, Orlov SV et al. Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer. J Thorac Oncol 2011; 6: 781-785.
25. Heist RS, Fain J, Chinnasami B et al. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. J Thorac Oncol 2010; 5: 1637-1643.
26. Sternberg CN, Dumez H, Van Poppel H et al. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol 2009; 20: 1264-1269.
27. Kelly WK, Halabi S, Carducci MA et al. A randomized, double-blind, placebocontrolled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castrationresistant prostate cancer (mCRPC): survival results of CALGB 90401. J Clin Oncol 2010; 28Suppl18s. (Abstr LBA4511).
28. Chi KN, Hotte SJ, Yu EY et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castrationresistant prostate cancer. J Clin Oncol 2010; 2827: 4247-4254.
29. Chi KN, De Bono J, Higano CS et al. SYNERGY: a randomized phase III study comparing first-line docetaxel/prednisone to docetaxel/prednisone plus custirsen in metastatic castrate-resistant prostate cancer. J Clin Oncol 2011; 29Suppl (Abstr TPS180).
30. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 3635: 411-422.
31. McGregor N, Patel L, Craig M et al. AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model. J Cell Biochem 2010; 1105: 1187-1194.
32. Goldsmith KC, Lestini BJ, Gross M et al. BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists. Cell Death Differ 2010; 175: 872-882.